期刊
SEMINARS IN LIVER DISEASE
卷 32, 期 1, 页码 30-38出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0032-1306424
关键词
Nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; insulin resistance; hepatocellular carcinoma
资金
- Genentech
- Merck
- BMS
- Rottapharm
- Mochida
Nonalcoholic fatty liver disease (NAFLD) is easily themost common cause of chronic liver disease in the United States (U. S.) as the hepatic manifestation of the metabolic syndrome. Although only 5 to 20% of patients with NAFLD are generally considered to meet criteria for nonalcoholic steatohepatitis (NASH), with its inherent risk for progression to cirrhosis, this still represents an alarmingly large number of individuals. The exponentially growing rates of hepatocellular carcinoma (HCC) in the U. S. may be partially attributable to increased numbers of NASH cirrhotics, although recent evidence has suggested that NAFLD may directly promote hepatic carcinogenesis independent of cirrhosis. This review focuses on HCC in noncirrhotic NASH with an emphasis on clinical presentation, pathogenesis, and implications for screening.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据